8.63
+0.185(+2.19%)
Currency In USD
| Previous Close | 8.45 |
| Open | 8.91 |
| Day High | 9.1 |
| Day Low | 8.63 |
| 52-Week High | 9.1 |
| 52-Week Low | 1.78 |
| Volume | 1.01M |
| Average Volume | 326,216 |
| Market Cap | 188.66M |
| PE | -9.7 |
| EPS | -0.89 |
| Moving Average 50 Days | 7 |
| Moving Average 200 Days | 4.79 |
| Change | 0.19 |
If you invested $1000 in Exagen Inc. (XGN) since IPO date, it would be worth $504.38 as of July 30, 2025 at a share price of $8.63. Whereas If you bought $1000 worth of Exagen Inc. (XGN) shares 5 years ago, it would be worth $676.86 as of July 30, 2025 at a share price of $8.63.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Exagen Inc. Appoints Chas McKhann to Board of Directors
GlobeNewswire Inc.
Jul 17, 2025 8:05 PM GMT
CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors, effective July 17, 2025. Mr. Mc
Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025
GlobeNewswire Inc.
Jul 15, 2025 8:05 PM GMT
CARLSBAD, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2025, before the market opens on Tuesday, July 29, 202
Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics
GlobeNewswire Inc.
Jun 23, 2025 1:00 PM GMT
CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief Scientific Officer. With an extensive backgrou